One cohort of Phase 2 NSCLC study fails to meet primary endpoint, Merrimack says

[News]

Merrimack Pharmaceuticals, Inc. today announced that one cohort of a Phase 2 non-small cell lung cancer study did not meet its primary endpoint. The cohort evaluated MM-121 in combination with erlotinib to treat patients with NSCLC whose disease progressed on an anti-EGFR tyrosine kinase inhibitor (EGFR-TKI).

More... (http://www.news-medical.net/news/20130405/One-cohort-of-Phase-2-NSCLC-study-fails-to-meet-primary-endpoint-Merrimack-says.aspx)